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Introduction: The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo
assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET
studies have demonstrated significantly higher cortical retention of 18F-THK523 in AD compared to age-matched
healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies,
such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick’s disease (PiD).
Methods: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical
and fluorescence studies in serial brain sections taken from individuals with AD (n = 3), CBD (n = 2), PSP (n = 1), PiD
(n = 2) and Parkinson’s disease (PD; n = 2). In addition to the neuropathological analysis, one PSP patient had
undergone a 18F-THK523 PET scan 5 months before death.
Results: Although THK523 labelled tau-containing lesions such as neurofibrillary tangles and neuropil threads in the
hippocampus and frontal regions of AD brains, it failed to label tau-containing lesions in non-AD tauopathies.
Furthermore, though THK523 faintly labelled dense-cored amyloid-β plaques in the AD frontal cortex, it failed to
label α-synuclein-containing Lewy bodies in PD brain sections.
Conclusion: The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD
brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia (50% to 70% of dementia cases) [1]. At present,
there is no cure for the disease. Age is the greatest risk
factor. Despite the existence of distinctive clinical diag-
nostic criteria, the differential diagnosis of AD and other
neurodegenerative disorders is sometimes challenging be-
cause of substantial overlap in clinical presentations, espe-
cially at the early stages of the disease [2]. Consequently,
making the definitive diagnosis of neurodegenerative* Correspondence: m.fodero@unimelb.edu.au
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distribution, and reproduction in any mediumdiseases is still reliant upon postmortem examination
of the brain.
AD is pathologically characterised by the presence of
(1) extracellular neuritic plaques composed of aggre-
gated β-amyloid (Aβ) and (2) intracellular neurofibrillary
tangles (NFTs) composed of the aggregated tau protein
[3,4]. Tau aggregates are a pathological trait of not only
AD but also other neurodegenerative conditions, such as
corticobasal degeneration (CBD) and progressive supra-
nuclear palsy (PSP), as well as some variants of frontotem-
poral lobar degeneration (FTLD-tau) [5], such as Pick’s
disease (PiD). Whilst the underlying mechanism leading
to tau accumulation remains unclear, it is thought to be
related to several pathogenic events resulting in hyperpho-
sphorylation, misfolding and aggregation of tau. Tau ag-
gregation in this wide spectrum of tauopathies presentsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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astrocytes in CBD, globose tangles and thorny and tufted
astrocytes in PSP and Pick bodies in PiD [6-9]) and ul-
trastructural conformations (for example, paired helical
filaments in AD, straight filaments in PSP and twisted rib-
bons and random coils in PiD [6,10,11]), which are prob-
ably attributable to the combinations of the different tau
isoforms and a wide variety of posttranslation modifica-
tions [6,12]. Additionally, the spatial distribution of the
tau aggregates in these tauopathies differ from each other,
with NFTs in AD being prevalent in the mesial temporal
cortex and cortical grey-matter (GM) areas. Tau aggre-
gates are also found in the frontal and striatal brain re-
gions in CBD; in the brainstem, cerebellar white matter
and basal ganglia in PSP; and in the frontal and temporal
neocortex in PiD [13-17]. The diverse distribution of these
tau aggregates in the brain can potentially be useful in the
differential diagnosis of these tauopathies, assuming the
same tau imaging agent binds with similar affinity to the
whole spectrum of tau aggregates. Alternatively, the diffe-
rential diagnosis might require the development of select-
ive tau radiotracers for each specific conformation of tau
aggregates.
In recent years, a great deal of interest has been placed
on identifying the ideal diagnostic tool for neurodegen-
erative diseases. Despite the quantitative assessment of
Aβ, tau and phospho-tau in cerebrospinal fluid (CSF)
[18], lumbar puncture is still considered an invasive
procedure for the widespread screening of the ‘at-risk’
population. Additionally, CSF measurements do not pro-
vide information on regional brain deposition of Aβ or
tau, which may have clear correlates with cognition or
regional brain atrophy and might not be able to provide
important information regarding the therapeutic out-
comes or response to current drugs aimed at modulating
the deposition of these misfolded proteins [19-23]. Given
the sometimes nonspecific nature of clinical symptoms
and neuropsychological assessments, modern molecular
imaging techniques have proven beneficial in the nonin-
vasive identification of the underlying pathology of these
diseases. Considerable effort has been focused on the de-
velopment of novel Aβ ligands that permit detection of
Aβ deposition [24]. The Aβ-specific ligands 18F-AV-45
(florbetapir; (E)-4-(2-(6-(2-(2-(2-([18F]-fluoroethoxy)eth-
oxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine)
and Pittsburgh compound B (PiB) [25] are the best char-
acterized and have proven to be suitable positron emission
tomography (PET) biomarkers for the in vivo quantitation
of cerebral Aβ burden. They have demonstrated a robust
difference in retention between AD and healthy individ-
uals [25-27]. 18F-AV-45 [27] and flutemetamol 18 (2-[3-
fluoranyl-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol)
[28] have already been approved for clinical Aβ imaging in
the United States. These two agents belong to a secondgeneration of Aβ radiotracers labelled with 18F, which,
with a half-life of 110 minutes, allows a wider and more
cost-effective application of Aβ imaging.
We recently reported the preclinical characterization
of the selective tau radiotracer 18F-THK523 [29], a quin-
oline derivative pioneered by Okamura and colleagues
[30,31]. Preliminary clinical evaluation of 18F-THK523 has
demonstrated that 18F-THK523 retention is significantly
higher in the cortical and hippocampal GM of AD pa-
tients than in age-matched healthy individuals [32].
To discern whether 18F-THK523 recognises non-AD
tau aggregates in addition to NFTs, we evaluated a series
of brain sections from AD and non-AD tauopathies to




All reagents were purchased from Sigma-Aldrich (St
Louis, MO, USA) unless otherwise stated.
Tissue collection and characterisation
Tissues were sourced and prepared by the Victorian Brain
Bank Network. The AD pathological diagnosis was made
according to standard National Institute on Aging/Reagan
Institute criteria [5]. Determination of age-matched con-
trol cases were subject to the above-described criteria.
The pathological diagnoses of PiD, CBD and PSP were all
made according to previously described methods [33,34].
Ten cases were evaluated for this study: AD (n = 3), CBD
(n = 1), PiD (n = 2), PD (n = 1) and PSP (n = 3). One of the
individuals with PSP had undergone 18F-THK523 PET
5 months before death.
Immunohistochemistry and fluorescence analysis
All brain tissue was fixed in 10% neutral buffered forma-
lin, processed, and embedded in paraffin. For immuno-
histochemistry, 5-μm serial sections were deparaffinized
and treated with 90% formic acid for 5 minutes, and
endogenous peroxidase activity was blocked with 5% hy-
drogen peroxide. Sections were then treated with 0.2%
casein in Tris buffer before incubation with primary an-
tibodies to α-synuclein (97/8, 1:2,000 dilution) [35], Aβ
(1e8, 1:2,000 dilution; monoclonal antibody recognises
Aβ(17–24)) [36] and tau (polyclonal antibody recognises
C-terminal tau (amino acids 243 to 441), catalog no.
0024; Dako Denmark, Glostrup, Denmark), for 1 hour
at room temperature. Serial 5-μm tissue sections were
stained as follows. The first and third sections were im-
munolabelled with anti-97/8 antibody, anti-1e8 antibody
or tau to identify Lewy bodies, Aβ plaques or tau aggre-
gates, respectively. The second serial section was stained
with unlabelled THK523 to assess whether THK523 stai-
ning colocalised with the immunodetected Lewy bodies
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of antibody binding was achieved using the LSAB kit
(labelled streptavidin-biotin, catalog no. K0657; Dako
Denmark), then sections were incubated with hydro-
gen peroxidase diaminobenzidine (H2O2-DAB; Dako
Denmark) to visualise the α-synuclein-, Aβ- or tau-
positive deposits. Sections were counterstained briefly
(15 seconds) with Harris’s haematoxylin. To detect
THK523 fluorescence, quenching was first performed
whereby sections were first deparaffinized and tissue
autofluorescence was minimized by treatment of sec-
tions with 0.25% KMnO4 phosphate-buffered saline
(PBS) for 20 minutes prior to washing in PBS and in-
cubation with 1% potassium metabisulphite/1% oxalic
acid/PBS for 5 minutes. Following autofluorescence
quenching, sections were blocked in 2% bovine serum
albumin/PBS, pH 7.0, for 10 minutes and stained with
100 μM THK523 for 30 minutes. Sections washed in PBS
were then mounted in nonfluorescent mounting medium
(catalog no. S3023; Dako Denmark). Epifluorescent images
were visualized on a Leica microscope (47-nm cyan fluor-
escent protein, fluorescence filter set 47 (EM BP 436/20,
BS FT 455 and EM BP 480/40); Leica Microsystems,
North Ryde, 2113 Australia). Colocalisation of the
THK523 and antibody signals were assessed by over-
laying images from each of the stained serial tissue
sections.
Antemortem assessment
Five months before death, a seventy-nine-year-old pa-
tient diagnosed with PSP underwent an Aβ imaging PET
scan with 18F-florbetaben and a tau imaging scan with
18F-THK523. Approval of the study was granted by the
Austin Health Human Research Ethics Committee, and
written informed consent was obtained from all partici-
pants and caregivers before the study. The patient was
recruited, reviewed and diagnosed on the basis of clinical
and neuropsychological assessment by consensus of a
neurologist and a neuropsychologist.
As part of the imaging protocol, we performed magne-
tic resonance imaging (MRI) using a three-dimensional
magnetization-prepared rapid acquisition gradient echo
sequence and T2-weighted fast spin echo and fluid-
attenuated inversion recovery sequences. Both 18F-flor-
betaben and 18F-THK523 were synthesized at the Centre
for PET, Austin Health, as previously described [37-39].
PET scans were acquired using a Philips Allegro PET
scanner (Philips Healthcare, North Ryde, Australia) at
the Austin Health Centre. A transmission scan using a
rotating Cs-137 source was taken for attenuation correc-
tion immediately prior to obtaining the emission scan.
A 60-minute list-mode emission acquisition, followed
by a 90- to 120-minute acquisition using 10-minute
frames, was performed in three-dimensional mode afterinjection of 300 MBq of 18F-florbetaben. A 90-minute
list-mode emission image acquisition was performed in
three-dimensional mode after injection of 200 MBq of
18F-THK523. Images were reconstructed using a three-
dimensional row action maximum likelihood algorithm.
PET images were processed using a previously de-
scribed semiautomatic region of interest (ROI) method
[40]. Briefly, coregistration of the patient’s MRI scans
with the PET images was performed with Statistical
Parametric Mapping 8 (SPM8) software [41]. A narrow
cortical ROI template was placed on the coregistered
MRI scanner by an operator (VLV) who was blinded to
the participant’s clinical status, then it was transferred to
the coregistered PET images. The ROI template covered
cortical and subcortical GM structures as well as the
midbrain and pons. Subcortical white-matter ROIs were
placed at the centrum semiovale, and the cerebellar re-
gions were placed over the cerebellar cortex, taking care
to avoid white matter. Standardised uptake values (SUVs),
defined as the decay-corrected brain radioactivity concen-
tration normalized for injected dose and body weight,
were calculated for all regions. In order to avoid arterial
blood sampling, a simplified approach was applied using
the cerebellar cortex as the reference region. SUVs were
used to derive SUV ratios (SUVRs) referenced to the cere-
bellar cortex soon after the ratio of binding in neocortex
to that in the cerebellar cortex reached an apparent steady
state. Regional THK523 SUVRs were obtained for all re-
gions sampled. Global tau burden was expressed as the
average THK523 SUVR for the following cortical ROIs:
frontal (consisting of the dorsolateral prefrontal, ventrola-
teral prefrontal and orbitofrontal regions), superior par-
ietal, lateral temporal, lateral occipital, and anterior and
posterior cingulate. Partial volume correction accounting
for both GM atrophy and white-matter spillover was
performed using a three-compartment approach with
PMOD version 3.1 software (PMOD Technologies, Zurich,
Switzerland). To establish whether either 18F-florbetaben
or 18F-THK523 retention in the PSP patient was different
from age-matched controls, a Z-score was generated for
both global and regional retention. The respective Z-scores
were generated against ten healthy controls who had 18F-
florbetaben studies and ten healthy controls who had 18F-
THK523 studies. Conservative Z-scores greater than 1.5,
indicating just 1.5 standard deviations (SDs) from the mean
of the control participants, were considered abnormal.
Results
Demographic information
The demographics of the patients whose postmortem
human brain tissue was utilized for these studies, ex-
pressed as mean ± SD, are presented in Table 1. All par-
ticipants assessed were of similar age with comparable
postmortem intervals for tissue collection. The patient







AD 3 72.9 ± 6.7 22.8 ± 8.8
PSP 3 73.2 ± 4.6 37.2 ± 18.6
PiD 2 75.4 ± 7.1 47.0 ± 5.2
CBD 1 72.5 11.0
PD 1 70.5 22.5
aAD, Alzheimer’s disease; CBD, Corticobasal degeneration; PD, Parkinson’s
disease; PiD, Pick’s disease; PMI, Postmortem interval; PSP, Progressive
supranuclear palsy.
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11 years of formal education. A neuropsychological exa-
mination revealed the patient had a Mini Mental State
Examination score of 26, a Clinical Dementia Rating
Scale score of 1 a Clinical Dementia Rating Scale–Sum of
Boxes score of 5.5, an episodic memory composite score
of −3.22 and a nonmemory composite score of −3.40.
The PSP participant died 5 months after the PET scans
were taken.
Assessment of THK523 binding/fluorescence in
non–Alzheimer’s disease tauopathies
The results of our previous postmortem studies [29] have
indicated that THK523 labels AD tau lesions, namely,
NFTs in the hippocampus of patients with AD (Figure 1).
To determine whether THK523 would also bind to non-
AD tau lesions, brain sections from non-AD tauopathies
were evaluated. For these studies, fixed contiguous serial
sections from the striatum (CBD and PSP samples), the
frontal cortex (PiD sample) and the pons (PSP sample)
were either immunostained with a polyclonal tau anti-
body for the detection of tau lesions or incubated withFigure 1 THK523 binds to neurofibrillary tangles in an Alzheimer’s dise
of a representative Alzheimer’s disease patient. The left image (tau) is the first
to detect tau lesions in the hippocampus. The black arrow indicates the posit
indicated by the black arrow was transferred to subsequent adjacent serial se
immunostained with a monoclonal antibody raised to amyloid-β (Aβ) to iden
staining of THK523 (middle) appears to colocalise and resemble tau NFTs, ind
the same tissue region (right, red arrow). Tissue section images were obtained
Microscopy, North Ryde, Australia). Scale bars, 100 μm.the fluorescent compound THK523 to determine whether
THK523 bound to non-AD tauopathy aggregates. Immu-
nohistochemical staining of brain tissue regions rich in
tau immunoreactivity was detected by light microscopy,
and the same tissue region within the adjacent serial sec-
tion was assessed by fluorescence microscopy to compare
and determine whether the immunoreactive tau lesion
colocalised with THK523 binding, indicated by a fluo-
rescent signal. Immunohistological assessment of brain
sections from CBD and PiD patients revealed the charac-
teristic presence of globose tangles, coiled bodies (as indi-
cated by the arrowheads in the figures; see top left panel
of Figure 2) and Pick’s bodies (arrowheads in bottom left
panel of Figure 2) in the striatum and frontal cortex.
Nonetheless, examination of the same region within the
adjacent serial section exhibited no signs of THK523 fluo-
rescence, indicating that THK523 does not bind to these
tau lesions. Likewise, immunohistological evaluation of
the pons (left, top panel of Figure 3) and striatum (left,
bottom panel of Figure 2) in PSP patients revealed that,
despite the presence of tau globose tangles, there was no
detectable THK523 fluorescence signal in the same region
of the adjacent serial brain section, again suggesting that
THK523 does not bind to globose tangles. It is noteworthy
that one of the three PSP patients evaluated (Figure 3) had
had 18F-THK523 and 18F-florbetaben PET scans 5 months
prior to death. There was low 18F-florbetaben cortical re-
tention (Figure 4), correlating with postmortem results
showing absence of Aβ deposits. There was also low cor-
tical 18F-THK523 retention as well as low 18F-THK523
retention in the basal ganglia, midbrain, pons and cere-
bellar white matter (Figure 4), which was indistinguish-
able from age-matched controls and in contrast to the
relatively high density of tau lesions observed in thease patient. Microscopy of 5-μm serial sections from the hippocampus
of three serial sections. It is immunostained with tau polyclonal antibody
ioning of neurofibrillary tangles (NFTs). The positioning of the NFTs
ctions that were either stained with THK523 (middle image, THK523) or
tify senile plaques in the tissue section (right image, Aβ). Fluorescence
icated by the yellow arrow, in the absence of Aβ immunoreactivity in
using a Zeiss microscope and an AxioCam digital camera (Carl Zeiss
Figure 2 THK523 does not bind to tau lesions in corticobasal degeneration or Pick’s disease. Microscopy of 5-μm serial sections from the
striatum of a corticobasal degeneration (CBD) patient (top panel) and the frontal cortex of a Pick’s disease (PiD) patient (bottom panel). The left
side (Tau) shows the first of two serial sections immunostained with tau polyclonal antibodies to detect tau lesions. The arrows indicate the
positioning of brown immunostained globose tangles (GT) and coiled bodies (CB; top panel) in a CBD patient and Pick’s bodies and dystrophic
neurites (DN) (bottom panel). The same region of tissue was subsequently imaged for the adjacent section, which was stained with THK523
(right, THK523). The positioning of the tau lesion arrows was transferred to the adjacent stained serial section and is indicated by yellow arrows
(THK523). The absence of fluorescence suggests that THK523 does not bind to CBD or PiD tau lesions. Tissue sections were imaged using a Zeiss
microscope and an AxioCam digital camera at 5× (CBD) and 20× (PiD) original magnification.
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globose tangles. Analysis of the PSP patient PET scans
showed global and regional Z-scores less than 1.0 for
18F-THK523 and 18F-florbetaben, confirming the visual in-
spection of the images.
Assessment of THK523 binding/fluorescence in
Parkinson’s disease
To further test the selectivity of THK523, we evalua-
ted its ability to bind to Lewy bodies composed of α-
synuclein and ubiquitin aggregates sharing a similar
β-sheet secondary structure. For these studies, serial
sections of the substantia nigra from a PD patient were ei-
ther immunostained with antibodies raised to α-synuclein,
or treated with a fluorescent compound, THK523. Evalu-
ation of these stained serial sections demonstrated that,
whilst the presence of Lewy bodies could be clearly identi-
fied by immunohistochemistry (Figure 5, left panel), the
adjacent serial section was devoid of THK523 fluores-
cence (Figure 5, right panel), implying that THK523 did
not bind to Lewy bodies.Discussion
In the present study, we further characterized 18F-THK523
as a selective tau imaging agent by testing its ability to
recognize the various morphological conformations of tau
in a wide spectrum of tauopathies. Whilst in our previous
studies we determined that THK523 binds selectively to
NFTs in preference to Aβ plaques [29,32], in this study we
also assessed 18F-THK523 binding to other β-sheet struc-
tured protein fibrils, namely, α-synuclein-containing Lewy
bodies.
Given the morphological and ultrastructural diversity
of tau aggregates, it may be unlikely that a single tau im-
aging agent could be useful for the diagnosis of all tauo-
pathies. In the first instance, tau comprises six isoforms
distinguished by their length and number of repeats (R)
of microtubule binding domains [6,42]. AD tau com-
prises an equal ratio of the 3R and 4R isoforms, which
mainly appear as NFTs. The 4R isoform predominates in
PSP with tau aggregates comprising tufted-shaped astro-
cytes, GTs and oligodendroglial coiled bodies [43,44]. Des-
pite also being a 4R tauopathy, in CBD the tau inclusions
Figure 3 THK523 does not bind to globose tangles in a progressive supranuclear palsy patient. Microscopy of 5-μm serial sections taken
from the pons (top panels) and the striatum (bottom panels) of a representative progressive supranuclear palsy (PSP) patient. Left (Tau) images
show the first of two serial sections immunostained with a tau polyclonal antibody to detect globose tangles (GB). The black arrows indicate the
positioning of brown immunostained GBs in the tissue section examined. The same region of tissue was subsequently imaged for the adjacent
section, which was treated with THK523 (right, THK523). The positioning of the tau lesion black arrows was transferred to the adjacent stained
serial section and is indicated by the yellow arrows (THK523). The absence of fluorescence suggests that THK523 did not bind to the tau lesions
of the PSP patients examined. Tissue sections were imaged using a Zeiss microscope and an AxioCam digital camera at 5× original magnification.
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pretangles [45]. PiD, a 3R tauopathy, is diagnosed by the
presence of ‘Pick bodies’, tau-positive intraneuronal in-
clusions [46]. Moreover, these tau aggregates are further
differentiated by their ultrastructure. NFTs are predomi-
nantly composed of paired helical filaments (PHFs), tau
inclusions in PSP and CBD are composed predominantly
of straight tau filaments (SFs) and twisted tau filaments
(TFs) [11], whereas Pick bodies comprise a combination
of TFs and random coiled tau filaments [11]. It is note-
worthy that, whilst PSP and CBD share SFs, the size of the
filaments is significantly different [47]. Despite this diver-
sity, a recent report describing a novel class of tau tracers
phenyl/pyridinyl-butadienyl-benzothiazoles/benzothiazo-
liums (PBB) demonstrated binding to a variety of
tau deposits in fluorescence studies of AD, CBD and
PSP brain sections [48]. Additionally, that study also
demonstrated positive [11C]PBB3 PET scans in both AD
and CBD patients [48].Given the evident differences in THK523 staining, the
fluorescence microscopy studies we present herein dem-
onstrate that THK523, even at the very high concentration
of 100 μM, does not bind to non-PHF-tau aggregates. The
existence of a THK523 binding site on PHFs that is absent
in the other conformations is further emphasized by previ-
ous computerized cross-sectional and fragmentation stud-
ies which indicated that, whilst these types of filaments
share a similarly shaped morphological unit, the filament
arrangement is different [49].
PHFs appear as two filaments twisted around one an-
other with a cross-over repeat of 80 nm and an apparent
width varying between about 10 nm and 22 nm [50].
The resulting aggregate exhibits an amyloid structure
characterized by a β-sheet network forming the heart of
the protofibril network. This ultrastructural property
shared with Aβ and α-synuclein aggregates sometimes
results in the nonselective binding of imaging agents
[51]. As noted previously [29], in addition to THK523’s
Figure 4 18F-THK523 and 118F-florbetaben positron emission tomography scans in a progressive supranuclear palsy patient.
Representative 18F-florbetaben (18F-FBB, left) and 18F-THK523 (18F-THK, right) transaxial images at three different brain levels of a 79–year-old PSP
patient with a Mini Mental State Examination score of 26. Visual inspection reveals no cortical retention of either 18F-THK523 or 18F-florbetaben,
despite a postmortem immunohistological examination (see Figure 3 5 months after PET evaluation), confirming the presence of tau lesions.
SUVR, Standardised uptake value ratio.
Figure 5 THK523 does not bind to Lewy bodies in Parkinson’s disease patient. Microscopy of 5-μm serial sections from the substantia nigra
of a Parkinson’s disease patient. The left image (α-syn shows the first of two serial sections. It immunostained with an α-synuclein antibody to
detect Lewy bodies (LB) in the substantia nigra. The black arrows indicate the positioning of LBs. The same region of tissue was subsequently
imaged for the adjacent sections, which were treated with THK523. The positions indicated by the black arrows in the left panel were transferred
to the adjacent THK523 serial section and are indicated by the yellow arrows (THK523). The absence of fluorescence staining indicates that
THK523 does not bind to α-synuclein containing Lewy bodies in the same tissue region. Tissue sections were imaged using a Zeiss microscope
and an AxioCam digital camera at 5× original magnification.
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high tracer concentrations—10,000-fold higher than the
concentrations typically achieved during a PET scan—
demonstrated inconsistent THK523 staining of Aβ pla-
ques. THK523 stained the dense core of some Aβ pla-
ques in the frontal cortex of AD sections but did not
stain dense Aβ plaques in the hippocampus (Figure 1,
right panel). It is noteworthy that variable staining of
NFTs at high concentrations of PiB has also been re-
ported [52]. In addition to previous reports of in vitro
studies [29,30], several lines of evidence support the no-
tion that THK523 selectively binds to PHF-tau and does
not bind to Aβ in vivo: (1) Cortical THK523 retention
is significantly higher in AD; (2) THK523 retention
follows the known distribution of PHF-tau in the AD
brain; (3) PiB and THK523 show different brain re-
gional distribution patterns; (4) hippocampal THK523
retention significantly correlated with cognitive parame-
ters, but hippocampal PiB retention did not; and (5) hip-
pocampal THK523 retention significantly correlated with
hippocampal volume, but hippocampal PiB retention did
not [32].
The selectivity of THK523 for tau over other β-sheet
aggregated proteins was further demonstrated by fluo-
rescence microscopy studies showing the absence of
THK523 fluorescence in brain sections exhibiting immu-
nolabelled α-synuclein-containing Lewy bodies (Figure 5,
right panel).
The PSP patient showed neither 18F-THK523 nor 18F-flor-
betaben retention in the brain, suggesting the absence not
only of Aβ plaques but also of tau deposits. Neuropatho-
logical examination of the brain confirmed the absence of
Aβ plaques; however, typical tau lesions were present in
different brain regions that were not stained by THK523.
Given the ultrastructural diversity of tau aggregates, the
information derived from these THK523 studies is highly
valuable for the future design of tau imaging ligands.Conclusion
In the present study, we have demonstrated that THK523
selectively binds to PHF-tau with negligible binding to
PSP, CBD and PiD tau aggregates, as well as to Aβ and α-
synuclein aggregates. The results of this study also show
that novel tracers that bind to non-PHF tau aggregates
are needed.Abbreviations
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